首页 / 资讯详情
AI models need more data about biology, and OpenAI is paying to create it
摘要
Last year, the clinical trial policy analyst Ruxandra Teslo posted an idea for super-charging medical AI systems: use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data—information usually kept hidden as valuable trade secrets. She called these…
本站为资讯聚合平台，仅展示标题与摘要，原文版权归原发布方所有；如有侵权请联系我们删除。